FDA approves AstraZeneca’s Etcamah, opening ctDNA-guided treatment paradigm in breast cancer

In a rare divergence from its own expert panel, the FDA has granted accelerated approval to AstraZeneca’s camizestrant, turning a contentious regulatory review into a landmark win that opens a new treatment paradigm for molecular-guided cancer care.